Comparison of Nuclear Medicine Therapeutics Targeting PSMA among Alpha-Emitting Nuclides.

PSMA actinium-225 astatine-211 cytotoxicity double strand brake reproductive capability

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
11 Jan 2024
Historique:
received: 30 11 2023
revised: 05 01 2024
accepted: 07 01 2024
medline: 23 1 2024
pubmed: 23 1 2024
entrez: 23 1 2024
Statut: epublish

Résumé

Currently, targeted alpha therapy (TAT) is a new therapy involving the administration of a therapeutic drug that combines a substance of α-emitting nuclides that kill cancer cells and a drug that selectively accumulates in cancer cells. It is known to be effective against cancers that are difficult to treat with existing methods, such as cancer cells that are widely spread throughout the whole body, and there are high expectations for its early clinical implementation. The nuclides for TAT, including

Identifiants

pubmed: 38256007
pii: ijms25020933
doi: 10.3390/ijms25020933
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Japan Agency for Medical Research and Development
ID : JP23ym0126091
Organisme : JAEA and the GIMRT Collaborative Research Program of the Institute for Materials Research, Tohoku University
ID : 202212-RDKGE-0046

Auteurs

Kazuko Kaneda-Nakashima (K)

Laboratory of Radiation Biological Chemistry, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan.
MS-CORE, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan.
Department of Science, Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan.

Yoshifumi Shirakami (Y)

MS-CORE, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan.
Department of Science, Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan.

Yuichiro Kadonaga (Y)

MS-CORE, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan.
Nuclear Medicine, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan.

Tadashi Watabe (T)

MS-CORE, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan.
Nuclear Medicine, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan.

Kazuhiro Ooe (K)

MS-CORE, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan.
Radioisotope Research Center, Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan.

Xiaojie Yin (X)

Nishina Center for Accelerator-Based Science Nuclear Chemistry Group, RIKEN, Wako 351-0198, Japan.

Hiromitsu Haba (H)

Nishina Center for Accelerator-Based Science Nuclear Chemistry Group, RIKEN, Wako 351-0198, Japan.

Kenji Shirasaki (K)

Laboratory of Alpha-Ray Emitters, Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan.

Hidetoshi Kikunaga (H)

Research Center for Electron Photon Science, Tohoku University, Sendai 982-0826, Japan.

Kazuaki Tsukada (K)

Research Group of Heavy Element Nuclear Science, Advanced Science Research Center, Japan Atomic Energy Agency, Naka-gun 319-1195, Japan.

Atsushi Toyoshima (A)

MS-CORE, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan.
Department of Science, Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan.

Jens Cardinale (J)

Nuclear Medicine Department, University Hospital Düsseldorf, 40225 Düsseldorf, Germany.

Frederik L Giesel (FL)

Nuclear Medicine Department, University Hospital Düsseldorf, 40225 Düsseldorf, Germany.

Koichi Fukase (K)

MS-CORE, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan.
Department of Science, Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan.
Natural Product Chemistry, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan.

Classifications MeSH